Publication Name	World Journal of Gastroenterology
Manuscript ID	8095
Country	United States

Received	2013-12-15 17:13
Peer-Review Started	2013-12-16 10:56
To Make the First Decision	2014-01-15 13:14
Return for Revision	2014-01-20 18:59
Revised	2014-02-28 23:52
Second Decision	2014-05-05 08:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-05 09:50
Articles in Press	2014-05-23 09:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-20 15:48
Publish the Manuscript Online	2014-11-17 15:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Metformin does not improve survival in patients with hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Mamatha Bhat, Roongruedee Chaiteerakij, William S Harmsen, Cathy D Schleck, Ju Dong Yang, Nasra H Giama, Terry M Therneau, Gregory J Gores and Lewis R Roberts
Funding Agency and Grant Number	Funding Agency Grant Number National Institutes of Health NCI CA165076 Mayo Clinic Center for Cell Signaling in Gastroenterology NIDDK P30DK084567 Mayo Clinic Cancer Center NCI CA15083 Mayo Clinic Center for Clinical and Translational Science NCATS UL1 TR000135
Corresponding Author	Lewis R Roberts, MBChB, PhD, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States. roberts.lewis@mayo.edu
Key Words	Hepatocellular carcinoma; Metformin; Diabetes; Survival; Liver disease; Lactic acidosis
Core Tip	Metformin has been shown to prevent the development of hepatocellular carcinoma (HCC) among patients with diabetes and chronic liver disease in retrospective studies. This agent results in inhibition of the mTOR pathway, integral to many malignancies. We investigated the role of metformin as a chemotherapeutic agent in HCC, by assessing whether its use in patients newly diagnosed with this cancer had improved survival as compared to diabetics on other hypoglycemic agents and those without diabetes. Our analysis clearly reveals that there is no overall survival benefit in using metformin for those patients newly diagnosed with HCC.
Publish Date	2014-11-17 15:12
Citation	Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 2014; 20(42): 15750-15755
URL	http://www.wjgnet.com/1007-9327/full/v20/i42/15750.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i42.15750

Full Article (PDF)	WJG-20-15750.pdf
Full Article (Word)	WJG-20-15750.doc
Manuscript File	8095-Review.docx
Answering Reviewers	8095-Answering reviewers.pdf
Copyright License Agreement	8095-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20131215043148.doc
Peer-review Report	8095-Peer review(s).pdf
Scientific Editor Work List	8095-Scientific editor work list.pdf